<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2104</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CORONARY HEART DISEASE</subject></subj-group></article-categories><title-group><article-title>Оценка эффективности вторичной профилактики у больных стабильной стенокардией</article-title><trans-title-group xml:lang="en"><trans-title>Secondary prevention effectiveness in patients with stable angina</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутлу</surname><given-names>Расим</given-names></name><name name-style="western" xml:lang="en"><surname>Kutlu</surname><given-names>Rasim</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант кафедры “Внутренних болезней 6 курса”</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мураталиев</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Murataliev</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>зав. отделением КБС НЦКиТ при МЗ КР и проф. кафедры “Внутренних болезней 6 курса” КГМА</p></bio><email xlink:type="simple">murataliev@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Кыргызская государственная медицинская академия</institution></aff><aff xml:lang="en"><institution>Kyrgyz Sate Medical Academy</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Кыргызская государственная медицинская академия;&#13;
Национальный центр кардиологии и терапии имени академика Мирсаида Миррахимова</institution></aff><aff xml:lang="en"><institution>Kyrgyz Sate Medical Academy;&#13;
Academician Mirsaid Mirrakhimov National Centre of Cardiology and Therapy. Bishkek</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>08</month><year>2010</year></pub-date><volume>9</volume><issue>4</issue><fpage>45</fpage><lpage>48</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кутлу Р., Мураталиев Т.М., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Кутлу Р., Мураталиев Т.М.</copyright-holder><copyright-holder xml:lang="en">Kutlu R., Murataliev T.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2104">https://cardiovascular.elpub.ru/jour/article/view/2104</self-uri><abstract><p>Цель. Оценить эффективность медикаментозной вторичной профилактики у амбулаторных больных со стабильной стенокардией (СС) в условиях реальной клинической практики. Материал и методы. Методом случайной выборки за период 2006 г проведен ретроспективный анализ 1067 амбулаторных карт пациентов со СС, находящихся на диспансерном учете в центрах семейной медицины г. Бишкек. Результаты. Основными классами антиангинальных препаратов (ААП), назначаемых врачами первичного звена, были β-адреноблокаторы 43,0 %, нитраты — 28,6 %, антагонисты кальциевых каналов — 27,9 %, реже применялись миокардиальные цитопротекторы — 0,5 %. Антиагреганты использовались в 86,8 % случаев, ингибиторы ангиотензин-превращающего фермента — у 82,2 % пациентов. Врачи первичного звена в условиях реальной клинической практики редко применяли гиполипидемические препараты — у 8,4 % больных. Использовались неадекватно низкие дозы, на уровне минимально эффективных, основных групп ААП. В 93,3 % случаев при лечении больных СС использовали генерические ААП и лишь в 6,7 % — оригинальные. Заключение. Медикаментозная вторичная профилактика у больных СС не в полном объеме соответствует современным рекомендациям.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To assess the effectiveness of pharmaceutical secondary prevention in ambulatory patients with stable angina (SA), in the real-worl clinical settings. Material and methods. Retrospective analysis of randomly selected ambulatory medical histories (n=1067; year 2006) of SA patients attending Bishkek centres of family medicine. Results. The main groups of anti-anginal medications (AAM), prescribed by primary healthcare doctors, were beta-adrenoblockers (BAB; 43,0 %), nitrates (28,6 %), and calcium antagonists (CA; 27,9 %). Anti-aggregants were prescirbed to 86,8 % of the patients, and ACE inhibitors — to 82,2 %. Myocardial cytoprotectors were prescribed less often (0,5 %), as well as lipid-lowering agents (8,4 %). The prescribed doses of lipid-lowering agents were inadequately low (minimal effective doses). Generic lipid-lowering medications were prescrbed more often (93,3 %) than the original ones (6,7 %). Conclusion. Pharmaceutical secondary prevention in SA patients was not adequate and did not comply with the modern clinical guidelines.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>стабильная стенокардия</kwd><kwd>фармакотерапия</kwd><kwd>вторичная профилактика</kwd></kwd-group><kwd-group xml:lang="en"><kwd>stable angina</kwd><kwd>pharmacotherapy</kwd><kwd>secondary prevention</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Здоровье населения и деятельность учреждений здравоохранения Кыргызской Республики. Бишкек 2000; 152 с.</mixed-citation><mixed-citation xml:lang="en">Здоровье населения и деятельность учреждений здравоохранения Кыргызской Республики. Бишкек 2000; 152 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Здоровье населения и деятельность учреждений здравоохранения Кыргызской Республики. Бишкек 2006; 275 с.</mixed-citation><mixed-citation xml:lang="en">Здоровье населения и деятельность учреждений здравоохранения Кыргызской Республики. Бишкек 2006; 275 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Информационный центр ВОЗ по здоровою население и здравоохранение в Центрально-азиатских республиках, Health of population and health care in central Asian republics WHO information center on health for. Carinfonet J 2000; 1: 3-15.</mixed-citation><mixed-citation xml:lang="en">Информационный центр ВОЗ по здоровою население и здравоохранение в Центрально-азиатских республиках, Health of population and health care in central Asian republics WHO information center on health for. Carinfonet J 2000; 1: 3-15.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">EUROASPIRE Study Group EUROASPIRE European Society of Cardiology survey of secondary prevention of coronary heart disease. Principal results. Eur Heart J 1999; 18: 1569-82.</mixed-citation><mixed-citation xml:lang="en">EUROASPIRE Study Group EUROASPIRE European Society of Cardiology survey of secondary prevention of coronary heart disease. Principal results. Eur Heart J 1999; 18: 1569-82.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">EUROASPIRE II Study Group Life style and risk factor management and use of drag therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programmer. Eur Heart J 2001; 22: 554-72.</mixed-citation><mixed-citation xml:lang="en">EUROASPIRE II Study Group Life style and risk factor management and use of drag therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II. Euro Heart Survey Programmer. Eur Heart J 2001; 22: 554-72.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Euro Heart Survey Programme ESC Quality Assurance Programme to Improve Cardiac Care in Europe. Euroaspire III Euro Heart Survey on Secondary and Primary Prevention Of Coronary Heart Disease. Euro Heart Survey ESC Сongress, Vienna, september 2007.</mixed-citation><mixed-citation xml:lang="en">Euro Heart Survey Programme ESC Quality Assurance Programme to Improve Cardiac Care in Europe. Euroaspire III Euro Heart Survey on Secondary and Primary Prevention Of Coronary Heart Disease. Euro Heart Survey ESC Сongress, Vienna, september 2007.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Eastaugh JL, Calvert MJ, Freemantle N, et al. Highlighting the need for better patient care instable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients Family Practice. Eur Heart J 2004; 21: 1-8.</mixed-citation><mixed-citation xml:lang="en">Eastaugh JL, Calvert MJ, Freemantle N, et al. Highlighting the need for better patient care instable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patients Family Practice. Eur Heart J 2004; 21: 1-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Witold R, Caroline AD, Anselm G, et al. Prospective observational study from the Euro heart survey of stable angina: Predicting prognosis instable angina—results. BMJ J 2006; 332: 262-7.</mixed-citation><mixed-citation xml:lang="en">Witold R, Caroline AD, Anselm G, et al. Prospective observational study from the Euro heart survey of stable angina: Predicting prognosis instable angina—results. BMJ J 2006; 332: 262-7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Strom BL. What is pharmacoepidemiology? 2nd еd. New York. John Wiley &amp; Sons, Inc. J 1994; 6: 3-15.</mixed-citation><mixed-citation xml:lang="en">Strom BL. What is pharmacoepidemiology? 2nd еd. New York. John Wiley &amp; Sons, Inc. J 1994; 6: 3-15.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Кардиоваск тер профил 2008г. http://familymedicine.ru/content/ view/246/32/</mixed-citation><mixed-citation xml:lang="en">Комитет экспертов ВНОК. Диагностика и лечение стабильной стенокардии. Российские рекомендации. Кардиоваск тер профил 2008г. http://familymedicine.ru/content/ view/246/32/</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kim F, Maria A, Diego A, et al. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 10: 1001-93.</mixed-citation><mixed-citation xml:lang="en">Kim F, Maria A, Diego A, et al. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 10: 1001-93.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Theodore D, Fraker J, Stephan D, et al. A Report of the American 2007 Chronic Angina Focused Updated of the ACC/ AHA 2002 Guidelines for the for the Management of Patients With Chronic Stable Angina. Circulation J 2007; 116: 1-12.</mixed-citation><mixed-citation xml:lang="en">Theodore D, Fraker J, Stephan D, et al. A Report of the American 2007 Chronic Angina Focused Updated of the ACC/ AHA 2002 Guidelines for the for the Management of Patients With Chronic Stable Angina. Circulation J 2007; 116: 1-12.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
